肺炎克雷伯碳青霉烯酶的研究进展  

Klebsiella pneumoniae Carbapenemase in Progress

作　　者：郝家砚[1,2] 徐元宏[1] 

机构地区：[1]安徽医科大学第一附属医院检验科,合肥230022 [2]安徽省立儿童医院检验科,合肥230051

出　　处：《国外医药（抗生素分册）》2011年第1期6-9,共4页World Notes on Antibiotics

摘　　要：肺炎克雷伯碳青霉烯酶型β-内酰胺酶(KPC)是近年来发现的肠杆菌科细菌对碳青霉烯酶抗生素耐药的主要机制,可水解除头霉素以外的所有β-内酰胺类抗生素。然而由于实验室检测KPC的及时性与准确性仍不能达到临床要求,这必将给一线的抗感染治疗和管理院内感染带来困难,因此,临床医师和实验室更应该重视,相互加强联系与沟通。Klebsiella pneumoniae carbapenemase-type β-1actamase is the main mechanism of antibiotic resistance ofEnterobacteriaceae carbapenemases, which was discovered in recent years. It can hydrolyzes all β-lactam antibiotics except eephamyein. However, due to the timeliness of laboratory testing and the accuracy of the KPC can not meet clinical requirements, which will give first-line anti-infection treatment and management of nosoeomial infections difficult, therefore, clinicians and laboratories should attach importance to each other to strengthen contact and communication.

关 键 词：肺炎克雷伯 碳青霉烯酶 检测 

分 类 号：R378.2[医药卫生—病原生物学]